Drugmaker Eli Lilly has announced it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom face increased financial difficulties due to the COVID-19 outbreak. This new co-pay scheme covers most of Lilly’s insulins, including the Humalog injection, and is available to people with or without insurance. Read more